Daniel Birnbaum (D Birnbaum)

Publication Activity (10 Years)

Years Active: 2020-2022
Publications (10 Years): 10

Top Topics

Acute Myeloid Leukemia

Diffusion Weighted

Top Venues

NPJ breast cancer

EMBO molecular medicine

Blood cancer journal

This page only lists publications with an associated author ORCID identifier.

Publications

Olivier Cabaud, Ludovic Berger, Emerence Crompot, José Adélaide, Pascal Finetti, Sèverine Garnier, Arnaud Guille, Nadine Carbuccia, Anne Farina, Emilie Agavnian, Max Chaffanet, Anthony Goncalves, Emmanuelle Charafe-Jauffret, Emilie Mamessier, Daniel Birnbaum, François Bertucci, Marc Lopez
Overcoming Resistance to Anti-Nectin-4 Antibody-Drug Conjugate. Molecular cancer therapeutics 21 (7) (2022)
Violette Azzoni, Julien Wicinski, Manon Macario, Martin Castagné, Pascal Finetti, Katerina Ambrosova, Célia D Rouault, Arnaud Sergé, Anne Farina, Emilie Agavnian, Sergiu Coslet, Emmanuelle Josselin, Arnaud Guille, José Adelaide, Emmanouil Zacharioudakis, Rémy Castellano, Francois Bertucci, Daniel Birnbaum, Raphaël Rodriguez, Emmanuelle Charafe-Jauffret, Christophe Ginestier
BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells. Cell death & disease 13 (2) (2022)
Alexandre de Nonneville, Sebastien Salas, François Bertucci, Alexander P Sobinoff, José Adélaïde, Arnaud Guille, Pascal Finetti, Jane R Noble, Dimitri Churikov, Max Chaffanet, Elise Lavit, Hilda A Pickett, Corinne Bouvier, Daniel Birnbaum, Roger R Reddel, Vincent Geli
TOP3A amplification and ATRX inactivation are mutually exclusive events in pediatric osteosarcomas using ALT. EMBO molecular medicine 14 (10) (2022)
Charlotte Rypens, François Bertucci, Pascal Finetti, Fredika Robertson, Sandra V Fernandez, Naoto Tada Ueno, Wendy A Woodward, Kenneth Van Golen, Peter Vermeulen, Luc Dirix, Patrice Viens, Daniel Birnbaum, Gayathri R Devi, Massimo Cristofanilli, Steven Van Laere
Comparative transcriptional analyses of preclinical models and patient samples reveal MYC and RELA driven expression patterns that define the molecular landscape of IBC. NPJ breast cancer 8 (1) (2022)
Justine Decroocq, Rudy Birsen, Camille Montersino, Prasad Chaskar, Jordi Mano, Laury Poulain, Chloe Friedrich, Anne-Sophie Alary, Hélène Guermouche, Ambrine Sahal, Guillemette Fouquet, Mathilde Gotanègre, Federico Simonetta, Sarah Mouche, Pierre Gestraud, Auriane Lescure, Elaine Del Nery, Claudie Bosc, Adrien Grenier, Fetta Mazed, Johanna Mondesir, Nicolas Chapuis, Liza Ho, Aicha Boughalem, Marc Lelorc'h, Camille Gobeaux, Michaela Fontenay, Christian Recher, Norbert Vey, Arnaud Guillé, Daniel Birnbaum, Olivier Hermine, Isabelle Radford-Weiss, Petros Tsantoulis, Yves Collette, Rémy Castellano, Jean-Emmanuel Sarry, Éric Pasmant, Didier Bouscary, Olivier Kosmider, Jérome Tamburini
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia. Leukemia 36 (5) (2022)
Anthony Goncalves, Pascal Finetti, Daniel Birnbaum, François Bertucci
The CINSARC signature predicts the clinical outcome in patients with Luminal B breast cancer. NPJ breast cancer 7 (1) (2021)
Chaïma Cherif, Dang Tan Nguyen, Clément Paris, Thi Khanh Le, Thibaud Sefiane, Nadine Carbuccia, Pascal Finetti, Max Chaffanet, Abdessamad El Kaoutari, Julien Vernerey, Ladan Fazli, Martin Gleave, Mohamed Manai, Philippe Barthélémy, Daniel Birnbaum, François Bertucci, David Taïeb, Palma Rocchi
Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity. Oncogene (2021)
Racha Fayad, Monserrat Vázquez Rojas, Mariagrazia Partisani, Pascal Finetti, Shiraz Dib, Sophie Abelanet, Virginie Virolle, Anne Farina, Olivier Cabaud, Marc Lopez, Daniel Birnbaum, François Bertucci, Michel Franco, Frédéric Luton
EFA6B regulates a stop signal for collective invasion in breast cancer. Nature communications 12 (1) (2021)
A Collignon, M A Hospital, C Montersino, F Courtier, A Charbonnier, C Saillard, E D'Incan, B Mohty, A Guille, J Adelaïde, N Carbuccia, S Garnier, M J Mozziconacci, C Zemmour, J Pakradouni, A Restouin, R Castellano, M Chaffanet, Daniel Birnbaum, Y Collette, N Vey
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study. Blood cancer journal 10 (6) (2020)
François Bertucci, Pascal Finetti, Anthony Goncalves, Daniel Birnbaum
The therapeutic response of ER+/HER2- breast cancers differs according to the molecular Basal or Luminal subtype. NPJ breast cancer 6 (2020)